Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression

Annals of Clinical Psychiatry

Volumn 9, Issue 3, 1997, Pages 157-164

  Cunningham, Lynn A ^a  

^a Vine Street Clinical Research Center ^*  (United States)

Author keywords

Clinical trial; Extended release; Major depressive disorder; Venlafaxine

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

AGED; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DREAMING; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHI-SQUARE DISTRIBUTION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0030779482     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026277907818     Document Type: Article

References (22)

1. Muth EA, Haskins JT, Moyer JA, et al: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Phamacol 1986; 35:4493-4497.
2. Benkert O, Gründer G, Wetzel, H, et al: A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996; 30:441-451
3. Clerc GE, Ruimy P, Verdeau-Pailles J: A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9:138-143.
4. Cunningham LA, Borison RL, Carman JS, et al: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14:99-106.
5. Dierick M, Ravizza L, Realini R, et al.: A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20:57-71.
6. Lecrubier Y, Moon CAL, Schifano F, et al.: Double-blind, randomized, placebo-controlled comparison of venlafaxine and imipramine in general practice patients with mild to moderate depression. Acta Psychiatr Scand 1997; 95:485-493
7. Rudolph R, Feighner J, Rickels K: A double-blind, randomized, placebo-controlled trial of venlafaxine in outpatients with major depression. J Clin Psychiatry 1997 (in press)
8. Schweizer E, Feighner J, Mandos L, et al.: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994; 55:104-108
9. Shrivastava R, Cohn C, Crowder J, et al.: Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14:322-329
10. Tylee A, Bowden M, Reynolds A, et al. A double-blind, randomized, 12-week comparison study of the safety and efficiency of venlafaxine and fluoxetine 20 mg in moderate to severe depression in general practice. Primary Care Psychiatry 1997; 3:51-58
11. Holliday SM, Benfield P, Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49:280-294
12. Hamilton MA: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
13. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
14. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institutes of Mental Health, 1976
15. Entsuah R, Upton GV, Rudolph R. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis. Hum Psychopharmacol 1995; 10:195-200
16. Guelfi JD, White C, Hackett D, et al.: Effectiveness of venlafaxine in patients hospitalized with major depression and melancholia. J Clin Psychiatry 1995; 56:450-458
17. Khan A, Rudolph R, Baumel B, et al.: Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharmacol Bull 1995; 31:753-758
18. Michels R, Marzuk PM: Progress in psychiatry. N Engl J Med 1993; 329:628-638
19. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991; 325:633-642
20. Preskorn SH, Janicak PG, Davis JM, et al.: Advances in the pharmacotherapy of depressive disorders. In: Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr, eds. Principles and Practice of Psychopharmacotherapy, Vol. 1, No. 2. Baltimore: Williams and Wilkins; 1995
21. Ereshefsky L: Drug-drug interactions involving antidepressants: Focus on venlafaxine. J Clin Psychopharmacol 1996; 16 (Suppl 2):37S-53S
22. Ferguson J, Khan A, Kucharik R, et al.: A placebo-controlled comparative study of the effects of blood pressure and antidepressant efficacy of venlafaxine and imipramine. Neuropsychopharmacology 1994; 10:117 (abstract)